Forte Q2 net loss $3.0M; cash $38.5M; FB-102 on track for late 2023/early 2024

Forte Biosciences, Inc.

2022-Q2 EPS reported -$0.38

Net loss $3.0M for Q2 2022 ($0.21 per share), compared to $5.8M loss ($0.43) in Q2 2021.
Cash and equivalents $38.5M as of June 30, 2022; raised $7.0M via ATM in July/August.
R&D spend down to $1.0M from $3.5M YoY as FB-401 wound down; focus shifting to autoimmune pipeline.
Lead candidate FB-102 expected to enter clinic late 2023 or early 2024 for GvHD, vitiligo, alopecia areata.
Appointed Hubert Chen as CSO and President; added Stephen Doberstein to board of directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.